Análisis Argos
IRTC
IRTCSin veredicto1 señal de riesgo
iRhythm Technologies, Inc. · Healthcare
US$ 126.48
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
36/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
Sin recompensas destacadas.
Riesgos
!Balance frágil: la deuda pesa sobre el negocio.
!Altman Z'' en zona roja (0.92)
VALOR1/6FUTURO6/6PASADO2/6SALUD1/6DIVIDENDO1/6
El Iris de calidad
VALOR1/6FUTURO6/6PASADO2/6SALUD1/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial aceptable
SaludBalance frágil
DividendoEl dividendo aún duerme
Score Argos36de 100Sin veredicto
Ingresos27%
US$ 0.8 B
Margen operativo75%
-4.9%
Flujo de caja libre200%
US$ 0 B
Deuda neta
US$ 0.5 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 4.2B
P/E
EV/EBITDA
FCF yield0.8%
ROIC-5.7%
Margen operativo-4.9%
Crecim. ingresos+26.2%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

prnewswire.com · 3 jul
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
prnewswire.com · 2 jul
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
NEW YORK, July 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at iRhythm caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real-time monitor intended for high-risk patients.
globenewswire.com · 30 jun
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of  iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders.
reuters.com · 15 jun
iRhythm discloses cyber incident, says no impact on device systems, patient safety
iRhythm Holdings on Monday reported unauthorized activity involving data maintained on some third-party applications last week, but said ​it has not identified any impact on products, ‌patient safety or medical device systems from the cyber attack.
globenewswire.com · 19 may
iRhythm Holdings to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that the company will be participating in the following investor conferences.
marketbeat.com · 18 may
iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains
iRhythm Technologies NASDAQ: IRTC executives said the company is seeing continued business momentum after a favorable Medicare coverage update, a stronger-than-expected first quarter and progress on several product and margin initiatives.
seekingalpha.com · 13 may
iRhythm Holdings, Inc. (IRTC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
iRhythm Holdings, Inc. (IRTC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
zacks.com · 5 may
Wall Street Analysts Predict a 57.21% Upside in IRHYTHM HLDGS (IRTC): Here's What You Should Know
The consensus price target hints at a 57.2% upside potential for IRHYTHM HLDGS (IRTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.